Siemens Healthineers and Mayo Clinic are deepening their strategic alliance with the explicit aim of elevating patient outcomes in the realms of neurodegenerative disorders, prostate cancer management, and the treatment of metastatic liver lesions. A recently executed accord between these two entities is poised to augment the quality of care for individuals afflicted with these conditions and broaden their access to cutting-edge imaging modalities and interventional technologies.
The initial focus areas for this collaborative endeavor encompass:
- Neurodegenerative Disorders: The development and clinical implementation of artificial intelligence (AI)-driven magnetic resonance imaging (MRI) protocols are underway, designed to enhance diagnostic precision and facilitate more effective patient monitoring.
- Surgical Care Pathway Redesign: The application of digital twin technology is being explored to fundamentally transform the patient’s surgical journey, thereby improving their care experience and boosting operational effectiveness.
- Prostate Cancer: Collaborative investigations are being conducted into the potential of AI to reduce the necessity for biopsies and to seamlessly integrate advanced, minimally invasive imaging techniques into diagnostic and therapeutic interventions.
- Minimally Invasive, Image-Guided Interventional Suites: Dedicated environments are being established to leverage state-of-the-art image-guided technologies for the accurate identification and treatment of liver metastases.
- Ultra-High-Field MRI Innovation Center: This center will utilize ultra-high-field MRI protocols, capitalizing on the technology’s superior resolution and enhanced contrast capabilities, for both diagnostic purposes and surgical planning in complex neurological cases.
- Whole Body PET/CT & PET/MR Innovation Center: This initiative focuses on the application of whole-body PET/CT, with a particular emphasis on theranostic treatments for specific cancers, complemented by simultaneous anatomical and metabolic MR imaging to enable precise diagnostic and therapeutic planning.
Our overarching objective is to deliver care that is more precise, less invasive, and highly attuned to the individual requirements of each patient. Through the expansion of our partnership, we are positioned to integrate advanced imaging solutions, artificial intelligence, and novel treatment methodologies directly into the fabric of routine clinical practice, thereby offering patients the potential for earlier detection, more tailored treatment strategies, and ultimately, superior health outcomes.”
Eric Williamson, M.D., Professor and Chair, Diagnostic Radiology, Mayo Clinic
John Kowal, President and Head of the Americas at Siemens Healthineers, further commented: “The enhancement of diagnostic accuracy and therapeutic efficacy for neurodegenerative conditions and cancer aligns directly with our fundamental corporate mission. This collaboration with Mayo Clinic presents substantial opportunities to contribute to extending the longevity and improving the quality of life for patients.”
